Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Literature
1.
2.
Daly MB, Pilarski R, Axilibund JE et al (2016) Genetic/familial high-risk assessment: breast and ovarian NCCN guideline version 1.2016. J Natl Compr Canc Netw 14:153–162CrossRefPubMed
Metadata
Title
Patients with negative multi-gene panel testing: a back to the future paradox?
Author
Steven M. Sorscher
Publication date
01-07-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-017-9967-z

Other articles of this Issue 3/2017

Familial Cancer 3/2017 Go to the issue

Original Article

Novel and reported pathogenic variants in exon 11 of BRCA2 gene in a cohort of Sri Lankan young breast cancer patients

Short Communication

Embryonal rhabdomyosarcoma in a patient with a heterozygous frameshift variant in the DICER1 gene and additional manifestations of the DICER1 syndrome

REVIEW

The association between prognosis of breast cancer and first-degree family history of breast or ovarian cancer: a systematic review and meta-analysis

Original Article

Mutation screening of ACKR3 and COPS8 in kidney cancer cases from the CONFIRM study

Original Article

Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives

Original Article

Supporting disclosure of genetic information to family members: professional practice and timelines in cancer genetics
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits